GLI1 and neoplasm: ITZ has demonstrated tumor growth inhibition in tumors resistant to other Hh inhibitors.[36,37] Moreover, the exploration of additional HPIs, including Taladegib, TAK-441, LEQ 506, Imiquimod, and GLI inhibitors, is underway, aiming to establish a potent therapeutic arsenal against BCC.